Anonymous Client E — Biotech company with first-in-class neurology therapeutic for rare epilepsy
The therapeutic targeted a rare epilepsy syndrome affecting approximately 15,000 patients in the US and 25,000 in Europe. Phase II data showed a 45% seizure reduction versus baseline, with a favorable safety profile. However, the company had conducted a single-arm Phase II trial without a control group, which raised questions about regulatory acceptability. Two competitors with different mechanisms were already in Phase III for the same indication, creating urgency for an accelerated development path.
A biotech company with a first-in-class neurology therapeutic for a rare epilepsy syndrome needed a regulatory strategy across FDA, EMA, and PMDA. They had completed Phase II with promising efficacy data but had no regulatory strategy, no clarity on accelerated approval pathways, and no understanding of orphan drug designation potential. Their standard development plan projected a 2028 approval — 5 years away — which was uncompetitive given that 2 competitors had entered Phase III.
We conducted a comprehensive regulatory pathway analysis across FDA, EMA, and PMDA, mapping precedent approvals for rare epilepsy therapies, accelerated approval pathways, and designation opportunities. Our analysis covered 12 precedent approvals, 5 regulatory guidance documents, and 3 accelerated approval pathways. We delivered a regulatory strategy with timeline optimization, agency engagement recommendations, and a gap analysis on the Phase II data package.
Precedent approval mapping: Analyzed 12 rare epilepsy drug approvals across FDA, EMA, and PMDA over the past 10 years, including review pathways, endpoint requirements, and approval timelines
Accelerated pathway assessment: Evaluated FDA Accelerated Approval, EMA PRIME scheme, and PMDA Sakigake designation eligibility and requirements
Orphan drug designation analysis: Assessed orphan drug designation eligibility across 3 agencies, including prevalence thresholds, precedent designations, and benefits
Phase II data gap analysis: Reviewed the single-arm Phase II data against regulatory expectations, identifying gaps and mitigation strategies
Competitive regulatory intelligence: Analyzed regulatory strategies of 2 competing Phase III programs to identify differentiation opportunities
Agency meeting strategy: Designed a series of regulatory agency meetings (FDA Type B, EMA Scientific Advice, PMDA Pre-IND) to align on development plan
We delivered a regulatory strategy that projected 2026 approval — 2 years earlier than the standard pathway. Key recommendations included: (1) pursue FDA Accelerated Approval based on substantial evidence of seizure reduction from Phase II plus confirmatory Phase III, (2) apply for Orphan Drug Designation in US and EU immediately, (3) request FDA Breakthrough Therapy Designation based on Phase II data, (4) design a Phase III trial with a placebo-controlled design and a primary endpoint aligned with recent epilepsy approvals, (5) submit EMA PRIME application for accelerated European review, and (6) initiate PMDA Sakigake designation discussions.
Phase 1 (Weeks 1-4): Precedent approval mapping and accelerated pathway assessment across 3 agencies
Phase 2 (Weeks 3-7): Orphan drug designation preparation and submission for FDA and EMA
Phase 3 (Weeks 6-10): Breakthrough Therapy Designation briefing document preparation and FDA Type B meeting request
Phase 4 (Weeks 9-14): Phase III protocol design with regulatory input and EMA Scientific Advice preparation
Phase 5 (Weeks 13-17): EMA PRIME application and PMDA Sakigake designation discussions
Phase 6 (Weeks 17-20): Integrated regulatory strategy document and timeline finalization
| Metric | Before | After | Impact |
|---|---|---|---|
| Projected Approval Timeline | 2028 (standard) | 2026 (accelerated) | 24-month acceleration worth $340M in additional revenue |
| Orphan Drug Designation | Not applied | Secured (US + EU) | 7-year market exclusivity (US), 10-year (EU), fee waivers |
| Breakthrough Therapy Designation | Not considered | Granted by FDA | Rolling review, intensive FDA guidance, priority review voucher |
| EMA PRIME Eligibility | Not assessed | Eligible — application submitted | Accelerated EMA assessment, early Rapporteur engagement |
| Phase III Design Alignment | No agency input | Aligned via FDA Type B meeting | Reduced risk of regulatory rejection post-trial |
“We were planning a standard development path that would have put us 2 years behind competitors. Medifirm showed us that our Phase II data qualified for Breakthrough Therapy designation and accelerated approval. Getting to market 2 years earlier changed our entire commercial trajectory.”
VP, Regulatory Affairs
Anonymous Client E
Forecast
Accelerated approval pathway, orphan drug designation, and Breakthrough Therapy designation projected to enable market entry 24 months earlier than standard pathway, representing $340M+ in additional revenue.
Every engagement starts with understanding your unique strategic challenge. Partner with Medifirm to transform data into decisions.